Samsung Epis Holdings expands its global footprint with a new R&D hub in Beijing
Samsung Epis Holdings Co., Ltd. (KRX: —) has announced the inauguration of its first overseas research and development facility in China. The new center, located in Beijing’s Changping District and registered locally as Samsung Bioepis, marks a significant step in the company’s strategy to accelerate biopharmaceutical innovation beyond its South Korean base in Incheon.
The opening ceremony, held on 1 July 2026, was attended by senior executives of Samsung Epis Holdings and local officials from the Changping District. In a statement, the company highlighted that the Beijing site will focus on building a technology platform centered on antibody‑drug conjugates (ADCs). ADCs combine a targeting antibody with a cytotoxic drug via a chemical linker, enabling precise delivery to cancer cells while minimizing damage to healthy tissue. This platform is intended to strengthen Samsung Epis Holdings’ capabilities in new drug development, particularly in oncology.
Changping’s proximity to the Zhongguancun Life Science Park and major academic institutions such as Peking University and Tsinghua University provides the Beijing center with access to a robust research infrastructure and a talent pool of scientists and clinicians. The company expects full‑scale research operations to begin shortly after the ceremony, with the goal of integrating the new facility into its global R&D network.
Current performance snapshot
| Metric | Value |
|---|---|
| Close price (29 June 2026) | 430 000 KRW |
| 52‑week high (1 Jan 2026) | 773 000 KRW |
| 52‑week low (25 Nov 2025) | 329 000 KRW |
| Market cap | 10 699 710 398 464 KRW |
| P/E ratio | 21.68 |
Samsung Epis Holdings, founded in 2025 and operating in the health‑care sector, manages a portfolio of biopharmaceutical products. Its recent expansion into China aligns with its broader strategy to increase global research capacity and accelerate the development of next‑generation therapies.
Recent clinical milestones
On 29 June 2026, Samsung Bioepis (the biopharmaceutical arm of Samsung Epis Holdings) released interim Phase‑1 and Phase‑3 data for SB27, a planned biosimilar to Keytruda (pembrolizumab). The Phase‑1 study demonstrated pharmacokinetic equivalence between SB27 and the reference product Keytruda, while the Phase‑3 trial reported an equivalent objective response rate at week 24. These preliminary results reinforce the company’s scientific competence and its leadership position in the biosimilar market. According to the company, both studies are expected to conclude later in 2026.
Strategic implications
The establishment of the Beijing R&D center represents a dual advantage:
- Geographic diversification – By situating a core research hub in China, Samsung Epis Holdings gains proximity to a rapidly growing biotechnology ecosystem and a large patient population for clinical studies.
- Technology focus – Concentrating on ADCs positions the company at the forefront of precision oncology, complementing its existing portfolio of biosimilars.
Combined with the recent positive clinical data for SB27, these developments signal a concerted effort by Samsung Epis Holdings to broaden its therapeutic offerings and enhance access to lifesaving biologic treatments worldwide.
